Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Globenewswire· 2025-06-26 12:00
JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) ...
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
Globenewswire· 2025-06-26 12:00
ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile Full study data from both cohorts expected later this year BARCELONA, Spain, June 26, 2025 (GLOBE NEWSWIRE) -- The Australasian Gastro-In ...
Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
Globenewswire· 2025-06-26 12:00
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE’s proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitorAmong newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD’s focuse ...
ZenaTech Signs Offer to Acquire North Carolina Land Surveying Company to Expand State Operations and Government Customers
Globenewswire· 2025-06-26 12:00
VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, announces it has signed an offer to acquire a well-established North Carolina-based land surveying company with a strong government customer base. The proposed acquisition expands operations in the state when combined with a previously announced proposed land surve ...
LiveOne (Nasdaq: LVO) to Host Thursday, July 3rd Special Conference Call; Record Earnings, B2B Updates, Tesla Conversion and Substantial Ad Growth
Globenewswire· 2025-06-26 12:00
LOS ANGELES, June 26, 2025 (GLOBE NEWSWIRE) -- LiveOne (Nasdaq: LVO), an award-winning, creator-first, music, entertainment, and technology platform, announced today that it will be hosting a conference call on Thursday July 3, 2025, to discuss results for the fourth fiscal quarter ("Q4 Fiscal 2025”) and fiscal year ended March 31, 2025 ("Fiscal 2025") and provide a business update. To access the call, please use the following information: Q4 Fiscal 2025 and Fiscal 2025 Earnings Conference CallDate:Thursday ...
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Globenewswire· 2025-06-26 12:00
The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compl ...
Cerence AI Powers In-Car Experience in Premier German Automaker’s New Electric Sedan
Globenewswire· 2025-06-26 12:00
Cerence core tech supports agentic voice assistant experience, rolling out first in the automaker’s latest addition to its electric vehicle lineupBURLINGTON, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that its core technologies are supporting new agentic and generative AI capabilities in the next-generation of MBUX, rolling out first in the all-new and all-electric Mercedes-Benz C ...
authID Partners with Prove to Provide Deepfake‑Resistant Identity Verification Capabilities Globally and Defend Against AI‑Generated Fraud
Globenewswire· 2025-06-26 12:00
authID and Prove’s strategic partnership offers an advanced, biometric-driven solution designed to target AI‑generated deepfake fraud, protecting thousands of enterprise customers from synthetic identities and video-based impersonation attacks.Denver, CO, June 26, 2025 (GLOBE NEWSWIRE) -- authID (Nasdaq: AUID), a leading provider of secure biometric identity verification and authentication solutions, today announced a strategic partnership with Prove, the world’s most accurate identity verification and auth ...
AirJoule Technologies Announces Two New Appointments to its Board of Directors
Globenewswire· 2025-06-26 12:00
Incoming Board directors bring significant expertise in data centers and financial oversightRONAN, Mont., June 26, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), the developer of the transformational AirJoule® system for separating pure water from air, today announced that it has appointed Denise Sterling and Thomas Murphy to its Board of Directors to fill vacancies created by Paul Dabbar and Kyle Derham’s departures. Mr. Dabbar was conf ...
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
Globenewswire· 2025-06-26 12:00
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russel ...